Market Place
Sourcing Support
Actinium Reveals ATNM-400`s Strong Efficacy in Breast Cancer
02 Dec 2025 //
PR NEWSWIRE
Prestige Biopharma & Biosidus Ink Tuznue Deal in Latin America
26 Nov 2025 //
PR NEWSWIRE
Enquyst Debuts Chromatography-Free mAb IPP Tech And Wins Award
24 Nov 2025 //
PR NEWSWIRE
Zymeworks: Positive Phase 3 Ziihera Results in HER2+ GE Cancer
17 Nov 2025 //
GLOBENEWSWIRE
Ziihera Excels In Her2+ Gastroesophageal Cancer Phase 3 Trial
17 Nov 2025 //
PR NEWSWIRE
Poherdy, First Biosimilar To Roche`s Perjeta, Scores FDA Nod
14 Nov 2025 //
FIERCE PHARMA
Akari Therapeutics Presents Splicing-Targeted ADC Payload Data
10 Nov 2025 //
GLOBENEWSWIRE
Actinium Pharma To Present ATNM-400 Data In Breast Cancer
04 Nov 2025 //
PR NEWSWIRE
Destiny-Lung06 Trial Begins: Enhertu Phase 3 For 1St-Line HER2
30 Oct 2025 //
BUSINESSWIRE
Iambic Collaborates With Jazz Pharma On Her2+ Breast Cancer Study
21 Oct 2025 //
BUSINESSWIRE
Teva, Prestige Bio Sign Deal For Tuznue® Commercialization
20 Oct 2025 //
GLOBENEWSWIRE
Kelun-Biotech Ph3 Data Favors Trastuzumab Botidotin Over T-DM1
20 Oct 2025 //
PR NEWSWIRE
Enhertu+THP Yields 67% pCR in High-Risk HER2+ Breast Cancer
18 Oct 2025 //
BUSINESSWIRE
Enhertu Cuts Recurrence or Death Risk by 53% in Ph3 Breast Trial
18 Oct 2025 //
BUSINESSWIRE
ENHERTU® Preceded By THP Yields 67% Pathologic Response
18 Oct 2025 //
BUSINESSWIRE
Enhertu Cuts Recurrence Risk By 53% In High-Risk Her2 Cancer
18 Oct 2025 //
BUSINESSWIRE
Kelun-Biotech’s Trastuzumab Botidotin Approved by NMPA
17 Oct 2025 //
PR NEWSWIRE
Pfizer Scores Again In Her2-Positive Breast Cancer
14 Oct 2025 //
FIERCE PHARMA
Astrazeneca Pharma India Gets CDSCO Approval For Trastuzumab
04 Oct 2025 //
INDPHARMAPOST
ENHERTU THP Combo BLA Accepted for High-Risk HER2+ Breast Cancer
01 Oct 2025 //
BUSINESSWIRE
ENHERTU Shows iDFS Benefit in High-Risk Early Breast Cancer
29 Sep 2025 //
BUSINESSWIRE
ENHERTU + Pertuzumab Gets US Priority Review In 1L HER2+ Cancer
24 Sep 2025 //
BUSINESSWIRE
Kelun-Biotech To Share Clinical Study Results At 2025 Esmo
23 Sep 2025 //
PR NEWSWIRE
ENHERTU Type II Variation Validated in EU for HER2 Solid Tumors
11 Sep 2025 //
BUSINESSWIRE
BioNTech, DualityBio Ph 3 ADC Meets Goal in HER2+ Breast Cancer
06 Sep 2025 //
PRESS RELEASE
Aurobindo`s Unit Receive UK Approval for Biosimilar Breast Cancer
27 Aug 2025 //
BUSINESS STD
CuraTeQ Biologics`s Dazublys Receives Approval in Europe
30 Jun 2025 //
EMA
Celltrion`s Biologics Herzuma Receives Suppl Approval in US
22 May 2025 //
FDA
10-Year Data: Perjeta Regimen Cuts Breast Cancer Deaths
13 May 2025 //
BUSINESSWIRE
CHMP recommends label update for Roche`s Phesgo
30 Apr 2025 //
GLOBENEWSWIRE
Alligator Bioscience starts HLX22 Phase 2 trial in breast cancer
23 Apr 2025 //
ACCESSWIRE
Enhertu drives strong efficacy in first-line breast cancer
22 Apr 2025 //
BUSINESSWIRE
Improved HER2+ Breast Cancer Treatment with 3D Pathology: JelloX
16 Apr 2025 //
PR NEWSWIRE
Enhertu Approved in EU as First HER2 Therapy for HR+ Breast Cancer
05 Apr 2025 //
BUSINESSWIRE
ENHERTU® Phase 3 Trial Begins for HER2+ Advanced Gastric Cancer
01 Apr 2025 //
BUSINESSWIRE
Amgen`s Biologic Kanjinti Receives Suppl Approval in US
19 Dec 2024 //
FDA
First Shipment of Henlius Trastuzumab to U.S.
02 Dec 2024 //
PR NEWSWIRE
AstraZeneca’s Enhertu Wins China Reimbursement Despite Probe
30 Nov 2024 //
BLOOMBERG
Celltrion`s Biologic Herzuma Receives Suppl Approval in US
14 Nov 2024 //
FDA
Mylan Gmbh`s Biologic Ogivri Receives Suppl Approval in US
13 Nov 2024 //
FDA
Daiichi Sankyo partners Alteogen on subcutaneous Enhertu News
09 Nov 2024 //
PHARMAPHORUM
Govt asks manufacturers to cut price of 3 anti-cancer drugs
29 Oct 2024 //
ECONOMICTIMES
ENHERTU Granted Priority Review For HER2 Low Breast Cancer
30 Sep 2024 //
BUSINESSWIRE
Prestige`s Tuznue (trastuzumab) Receives Approval in Europe
19 Sep 2024 //
EMA
Accord BioPharma`s HERCESSI 420mg Receives FDA Approval for HER2 Cancers
18 Sep 2024 //
PR NEWSWIRE
KEYTRUDA Combo Improves OS In HER2+ Gastric Or GEJ Adenocarcinoma
14 Sep 2024 //
BUSINESSWIRE
ENHERTU Shows Activity In HER2+ Breast Cancer With Brain Metastases
13 Sep 2024 //
BUSINESSWIRE
Daiichi Sankyo Unveils New ADC Research in Multiple Cancers at WCLC and ESMO
04 Sep 2024 //
BUSINESSWIRE
Enliven Therapeutics Reports Q2 Results And Business Update
13 Aug 2024 //
GLOBENEWSWIRE
Genentech`s Trastuzumab; Hyaluronidase-Oysk Receives Suppl Approval in US
18 Jun 2024 //
FDA
Genentech Biologic Trastuzumab Receives Suppl Approval in US
18 Jun 2024 //
FDA
Astra`s Enhertu breast cancer trial shows `unprecedented` results
03 Jun 2024 //
REUTERS
ENHERTU Shows 13.2 Month PFS In HER2-Low/Ultralow Metastatic Breast Cancer
02 Jun 2024 //
BUSINESSWIRE
Accord BioPharma’s HERCESSI secures FDA approval
30 Apr 2024 //
PHARMACEUTICAL TECHNOLOGY
AZ, Daiichi tout Enhertu win in earlier, broader HER2-low cancer
29 Apr 2024 //
FIERCE PHARMA
FDA Approves Accord`s HERCESSI™, Herceptin® Biosimilar
29 Apr 2024 //
PR NEWSWIRE
ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow
29 Apr 2024 //
BUSINESSWIRE
US FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors
06 Apr 2024 //
REUTERS
Biocon Biologics partners with Sandoz Australia for Biosimilars
10 Feb 2024 //
INDIAN PHARMA POST
